CSL加拿大公司宣布,首例加拿大患者已在安大略省成功接受了Hemgenix®(Etranacogene Dezaparvovec)基因疗法,用于治疗血友病B。这一里程碑事件标志着该创新疗法在加拿大临床应用的正式开启。
CSL加拿大公司宣布,首例加拿大患者已在安大略省成功接受了Hemgenix®(Etranacogene Dezaparvovec)基因疗法,用于治疗血友病B。这一里程碑事件标志着该创新疗法在加拿大临床应用的正式开启。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.